In conclusion, mild hepatotoxicity was observed in patients with neuroblastoma receiving cyclophosphamide therapy, which was more frequent in patients with normal/rapid CYP2B6 metabolizing capacity than in those with poor/intermediate CYP2B6 phenotypes. This evidence concerns the gene CYP2B6 and neuroblastoma.